Paul Guedeney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3359184/publications.pdf

Version: 2024-02-01

546 4
papers cit

41,085 citations 78 h-index 188 g-index

556 all docs 556
docs citations

556 times ranked 28220 citing authors

#	Article	IF	CITATIONS
1	Clinical End Points in Coronary Stent Trials. Circulation, 2007, 115, 2344-2351.	1.6	4,993
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
3	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). European Journal of Cardio-thoracic Surgery, 2012, 42, S45-S60.	1.4	1,605
4	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1438-1454.	2.8	1,560
5	Bivalirudin for Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2006, 355, 2203-2216.	27.0	1,367
6	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	27.0	1,265
7	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus documentâ€. European Heart Journal, 2012, 33, 2403-2418.	2.2	900
8	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	27.0	833
9	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
10	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, The, 2021, 397, 2385-2438.	13.7	530
11	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
12	Comparison of Propensity Score Methods and Covariate Adjustment. Journal of the American College of Cardiology, 2017, 69, 345-357.	2.8	468
13	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	2.8	445
14	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation, 2018, 137, 2635-2650.	1.6	435
15	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
16	Valve Academic Research Consortium 3: Updated Endpoint Definitions for AorticÂValve Clinical Research. Journal of the American College of Cardiology, 2021, 77, 2717-2746.	2.8	416
17	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	2.8	405
18	Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation, 2017, 135, 2091-2101.	1.6	403

#	Article	IF	CITATIONS
19	Prevalence, Impact, and Predictive Value ofÂDetecting Subclinical Coronary and CarotidÂAtherosclerosis in Asymptomatic Adults. Journal of the American College of Cardiology, 2015, 65, 1065-1074.	2.8	379
20	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
21	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
22	Contrast-Associated Acute Kidney Injury. New England Journal of Medicine, 2019, 380, 2146-2155.	27.0	363
23	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	27.0	362
24	Incidence, Predictors, and Impact ofÂPost-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	2.8	344
25	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. JAMA Network Open, 2020, 3, e2013136.	5.9	344
26	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	2.8	343
27	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. European Heart Journal, 2021, 42, 1825-1857.	2.2	342
28	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
29	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
30	Duration of Dual Antiplatelet Therapy AfterÂDrug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1298-1310.	2.8	314
31	Characterization of Myocardial Injury in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2043-2055.	2.8	303
32	Macrophages, Smooth Muscle Cells, and Tissue Factor in Unstable Angina. Circulation, 1996, 94, 3090-3097.	1.6	296
33	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor–Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
34	Pre-Eclampsia and Future Cardiovascular Risk Among Women. Journal of the American College of Cardiology, 2014, 63, 1815-1822.	2.8	271
35	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	2.8	269
36	Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion forÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 71, 1528-1536.	2.8	266

3

#	Article	lF	CITATIONS
37	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	2.8	211
38	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. European Heart Journal, 2014, 35, 1533-1540.	2.2	210
39	Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease. Journal of the American College of Cardiology, 2014, 63, 62-70.	2.8	188
40	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
41	Standardized End Point Definitions for Coronary Intervention Trials. European Heart Journal, 2018, 39, 2192-2207.	2.2	179
42	ST-segment elevation myocardial infarction. Nature Reviews Disease Primers, 2019, 5, 39.	30.5	179
43	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. Journal of the American College of Cardiology, 2016, 68, 2733-2744.	2.8	160
44	Stent-Related Adverse Events >1 Year After PercutaneousÂCoronaryÂIntervention. Journal of the American College of Cardiology, 2020, 75, 590-604.	2.8	160
45	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	2.9	159
46	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. Journal of Allergy and Clinical Immunology, 2016, 138, 1712-1715.	2.9	156
47	Stable coronary artery disease: revascularisation and invasive strategies. Lancet, The, 2015, 386, 702-713.	13.7	152
48	Antithrombotic Treatment in Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 62, 2349-2359.	2.8	151
49	Prognosis of Patients With Non–ST-Segment–Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2014, 7, 285-293.	3.9	151
50	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
51	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ, The, 2021, 373, n1332.	6.0	144
52	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal, 2015, 169, 472-478.e5.	2.7	140
53	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology, 2020, 75, 2711-2722.	2.8	139
54	Periprocedural myocardial infarction and injury in elective coronary stenting. European Heart Journal, 2018, 39, 1100-1109.	2.2	136

#	Article	IF	CITATIONS
55	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation, 2021, 143, 479-500.	1.6	132
56	Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal Cardiovascular Imaging, 2018, 19, 1042-1050.	1.2	127
57	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. International Journal of Cardiology, 2015, 187, 90-96.	1.7	126
58	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	2.8	126
59	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. Journal of the American College of Cardiology, 2020, 75, 1676-1685.	2.8	124
60	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	2.8	122
61	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
62	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. Journal of the American College of Cardiology, 2017, 69, 3055-3066.	2.8	117
63	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	2.8	116
64	Sexâ€based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2015, 85, 359-368.	1.7	112
65	A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended StatinÂAllocation in Elderly People. Journal of the American College of Cardiology, 2016, 68, 881-891.	2.8	109
66	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, The, 2016, 387, 349-356.	13.7	109
67	Duration of Dual Antiplatelet Therapy AfterÂCoronary Stenting. Journal of the American College of Cardiology, 2015, 66, 832-847.	2.8	105
68	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	2.2	100
69	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 2017, 184, 81-87.	2.7	95
70	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2014, 35, 2285-2294.	2.2	93
71	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	2.2	92
72	Procedural Strategies to Reduce theÂlncidence of Contrast-Induced AcuteÂKidney Injury During PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1877-1888.	2.9	91

#	Article	IF	CITATIONS
73	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. European Heart Journal, 2018, 39, 4101-4108.	2.2	89
74	Timing of Staged Nonculprit ArteryÂRevascularization in Patients WithÂST-Segment Elevation MyocardialÂInfarction. Journal of the American College of Cardiology, 2019, 74, 2713-2723.	2.8	88
75	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	13.7	87
76	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
77	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	2.8	85
78	Acute and 30-Day Outcomes in WomenÂAfter TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	2.9	85
79	Long-Term Mortality and EarlyÂValveÂDysfunction AccordingÂtoÂAnticoagulation Use. Journal of the American College of Cardiology, 2019, 73, 13-21.	2.8	85
80	Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters. JAMA Cardiology, 2017, 2, 798.	6.1	84
81	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2020, 141, 1618-1627.	1.6	84
82	Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2020, 5, 881.	6.1	82
83	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80
84	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	2.2	79
85	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1-12.	2.9	77
86	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. European Heart Journal, 2019, 40, 1334-1340.	2.2	77
87	Coronary Calcification and Long-TermÂOutcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions, 2020, 13, 1417-1428.	2.9	77
88	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	6.1	76
89	Impact of Atrial Fibrillation in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes With) Tj ETQq1 1 0.78-2014, 113, 236-242.	4314 rgBT 1.6	Oyerlock 10
90	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet, The, 2020, 396, 1737-1744.	13.7	75

#	ARTICLE	IF	CITATIONS
91	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. International Journal of Cardiology, 2017, 231, 61-67.	1.7	71
92	Negative Risk Markers for Cardiovascular Events in the Elderly. Journal of the American College of Cardiology, 2019, 74, 1-11.	2.8	71
93	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	2.8	71
94	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	3.9	71
95	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	13.7	71
96	A Critical Appraisal of Aspirin in Secondary Prevention. Circulation, 2016, 134, 1881-1906.	1.6	70
97	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal, 2018, 200, 17-23.	2.7	69
98	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newerâ€generation DES: Findings from a large multiethnic registry. Catheterization and Cardiovascular Interventions, 2018, 91, 859-866.	1.7	69
99	Residual Inflammatory Risk in PatientsÂWith Low LDL Cholesterol LevelsÂUndergoing Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2019, 73, 2401-2409.	2.8	69
100	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	2.2	69
101	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet, The, 2021, 398, 1974-1983.	13.7	69
102	Long-Term Outcomes in Women and MenÂFollowing Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2020, 75, 1631-1640.	2.8	68
103	Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 543-551.	3.9	67
104	Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from) Tj ETQq0 0 0	rgBT6/Ove	rlo 6k 10 Tf 50
105	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Journal of the American College of Cardiology, 2020, 75, 578-586.	2.8	66
106	Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding. Journal of the American College of Cardiology, 2014, 63, 15-20.	2.8	64
107	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal, 2019, 40, 2070-2085.	2.2	64
108	Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008768.	3.9	63

#	Article	IF	CITATIONS
109	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2022, 15, 268-277.	2.9	62
110	Meta-Analysis of Trials on Mortality After Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Stable Coronary Heart Disease and Objective Evidence of Myocardial Ischemia. American Journal of Cardiology, 2015, 115, 1194-1199.	1.6	60
111	Bypass Surgery or Stenting for LeftÂMainÂCoronary Artery Disease in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 1616-1628.	2.8	60
112	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	2.8	60
113	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 72, 754-765.	2.8	59
114	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2124-2133.	2.9	58
115	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. Journal of the American College of Cardiology, 2017, 70, 1846-1857.	2.8	58
116	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. European Heart Journal,	2.2	58
117	2018, 39, 2460-2468. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. European Heart Journal, 2016, 37, 3440-3447.	2.2	57
118	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
119	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	2.2	57
120	Sexâ€related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheterization and Cardiovascular Interventions, 2017, 89, 629-637.	1.7	56
121	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	2.9	56
122	Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease. JACC: Cardiovascular Interventions, 2018, 11, 833-843.	2.9	55
123	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	3.9	55
124	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. JACC: Cardiovascular Interventions, 2020, 13, 375-387.	2.9	55
125	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
126	Contrast-induced acute kidney injury. Cardiovascular Intervention and Therapeutics, 2020, 35, 209-217.	2.3	54

#	Article	IF	Citations
127	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
128	Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). American Journal of Cardiology, 2014, 114, 1823-1829.	1.6	53
129	Acute myocardial infarction in young women: current perspectives. International Journal of Women's Health, 2018, Volume 10, 267-284.	2.6	53
130	Left Ventricular Thrombus Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1010-1022.	2.8	53
131	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. JAMA Cardiology, 2021, 6, 410.	6.1	52
132	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	2.9	51
133	Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2016, 32, 226-233.	1.7	51
134	First Report of the Resolute Onyx 2.0-mmÂZotarolimus-Eluting Stent for the Treatment of Coronary Lesions With VeryÂSmall Reference Vessel Diameter. JACC: Cardiovascular Interventions, 2017, 10, 1381-1388.	2.9	50
135	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	2.2	49
136	Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 1966-1974.	2.9	49
137	Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training. JACC: Cardiovascular Interventions, 2019, 12, 219-228.	2.9	49
138	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
139	Prognostic Impact of Race in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2020, 13, 1586-1595.	2.9	49
140	Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis, 2012, 221, 176-182.	0.8	46
141	Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation. JAMA Cardiology, 2017, 2, 1303.	6.1	46
142	Radiationâ€associated lens changes in the cardiac catheterization laboratory: Results from the IC ATARACT (CATaracts Attributed to RAdiation in the CaTh lab) study. Catheterization and Cardiovascular Interventions, 2018, 91, 647-654.	1.7	46
143	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. International Journal of Cardiology, 2018, 268, 61-67.	1.7	46
144	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry. Circulation: Cardiovascular Interventions, 2021, 14, e010195.	3.9	46

#	Article	IF	CITATIONS
145	Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 372-379.	2.9	45
146	Cerebral Embolism During TranscatheterÂAortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 589-599.	2.8	45
147	Reperfusion strategies in acute myocardial infarction and multivessel disease. Nature Reviews Cardiology, 2017, 14, 665-678.	13.7	45
148	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. Journal of the American College of Cardiology, 2021, 77, 2960-2972.	2.8	45
149	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	3.0	45
150	Sex-Based Differences in AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Imaging, 2016, 9, 451-464.	5.3	43
151	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nature Reviews Cardiology, 2021, 18, 37-57.	13.7	42
152	Radial versus femoral access for coronary interventions: An updated systematic review and metaâ∈analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, 1387-1396.	1.7	42
153	Effects of Ticagrelor Versus Clopidogrel inÂTroponin-Negative Patients With Low-Risk ACS Undergoing AdÂHoc PCI. Journal of the American College of Cardiology, 2016, 67, 603-613.	2.8	41
154	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2017-2025.	2.9	41
155	Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	41
156	Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart, 2018, 104, 767-772.	2.9	41
157	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
158	Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65, 2714-2723.	2.8	40
159	Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data RegistryÂ $^{\circ}$. Catheterization and Cardiovascular Interventions, 2016, 87, 663-668.	1.7	40
160	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. American Heart Journal, 2016, 171, 40-47.	2.7	40
161	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 225-235.	3.0	40
	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary		

Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary
Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing) Tj ETQq0 0 p.rgBT /Oyerlock 10 of Cardiology, 2017, 119, 1710-1716.

#	Article	IF	CITATIONS
163	Overcoming Lack of Diversity in Cardiovascular Clinical Trials. Circulation, 2019, 140, 1690-1692.	1.6	39
164	Duration of Dual Antiplatelet Therapy forÂPatients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	2.8	39
165	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the) Tj ETQq1 1 0. American Journal of Cardiology, 2014, 114, 9-16.	784314 rş 1.6	gBT /Overloc 38
166	Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES,) Tj ETQq0 (0 0 rgBT /0)verlock 10 1
167	Current challenges for clinical trials of cardiovascular medical devices. International Journal of Cardiology, 2014, 175, 30-37.	1.7	37
168	Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. American Heart Journal, 2015, 170, 371-379.	2.7	37
169	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention WithÂStents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	2.9	37
170	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq0 C	Oor.geBT/C)vestock 10 T
171	Debris Heterogeneity Across DifferentÂValve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1262-1273.	2.9	36
172	Impact of calcification on percutaneous coronary intervention: MACEâ€Trial 1â€year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	1.7	36
173	The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1450-1457.	2.9	35
174	Gender differences in outcomes in patients with acute coronary syndrome in the current era: A review. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 51-60.	1.0	35
175	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	1.7	35
176	Trial Design Principles for Patients at HighÂBleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
177	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
178	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	2.9	34
179	Sex Disparities in Cardiovascular DeviceÂEvaluations. JACC: Cardiovascular Interventions, 2019, 12, 301-308.	2.9	34
180	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	13.7	34

#	Article	IF	CITATIONS
181	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	13.7	33
182	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
183	A Survey of Interventional Cardiologists' Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. JAMA Cardiology, 2018, 3, 629.	6.1	33
184	Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
185	The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. European Heart Journal Cardiovascular Imaging, 2015, 16, 81-87.	1.2	32
	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq0 0 0 rgBT /Overlo	ck 10 Tf 5	0 552 Td (No
186	Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
187	Correlates and Impact of Coronary ArteryÂCalcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
188	Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2017, 119, 1295-1301.	1.6	32
189	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	32
190	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in PatientsÂUndergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2015, 8, 1978-1987.	2.9	31
191	Effect of Chronic Kidney Disease in WomenÂUndergoing Percutaneous CoronaryÂIntervention With Drug-ElutingÂStents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
192	Effect of a Contrast Modulation SystemÂon Contrast Media Use and the Rate ofÂAcute Kidney Injury After Coronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1601-1610.	2.9	31
193	Aortic Valve Stenosis TreatmentÂDisparities in the Underserved. Journal of the American College of Cardiology, 2019, 74, 2313-2321.	2.8	31
194	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1†month of dual antiplatelet therapy. American Heart Journal, 2019, 214, 134-141.	2.7	31
195	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	2.9	31
196	Is Accurate Intravascular Ultrasound Evaluation of the Left Circumflex Ostium from a Left Anterior Descending to Left Main Pullback Possible?. American Journal of Cardiology, 2010, 105, 948-954.	1.6	30
197	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2014, 114, 1339-1346.	1.6	30
198	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	3.7	30

#	Article	IF	CITATIONS
199	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. American Journal of Cardiology, 2017, 119, 881-885.	1.6	29
200	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients TreatedÂWith Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	2.9	29
201	Balancing the Risk of Bleeding and Stroke in Patients WithÂAtrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	1.6	28
202	DAPT Duration After DES. Journal of the American College of Cardiology, 2015, 65, 1103-1106.	2.8	28
203	Preventing Contrast-induced Renal Failure: A Guide. Interventional Cardiology Review, 2016, 11, 98.	1.6	28
204	Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	28
205	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
206	Types of myocardial injury and mid-term outcomes in patients with COVID-19. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 438-446.	4.0	28
207	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	27
208	Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study). American Journal of Cardiology, 2017, 119, 1917-1923.	1.6	27
209	Transfemoral TAVR in Nonagenarians. JACC: Cardiovascular Interventions, 2019, 12, 911-920.	2.9	27
210	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	2.9	27
211	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1032.	6.1	27
212	Surgical Versus Percutaneous Coronary Revascularization for Multivessel Disease in Diabetic Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	26
213	Safety and efficacy of the next generation Resolute Onyx zotarolimusâ€eluting stent: Primary outcome of the RESOLUTE ONYX core trial. Catheterization and Cardiovascular Interventions, 2018, 92, 253-259.	1.7	26
214	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. American Heart Journal, 2017, 188, 73-81.	2.7	25
215	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	6.1	25
216	Effect of Procedure and Coronary LesionÂCharacteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 626-634.	2.9	25

#	Article	IF	CITATIONS
217	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. American Heart Journal, 2019, 208, 81-90.	2.7	25
218	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. Journal of Thrombosis and Thrombolysis, 2013, 35, 483-493.	2.1	24
219	Thrombus composition in sudden cardiac death from acute myocardial infarction. Resuscitation, 2017, 113, 108-114.	3.0	24
220	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	3.9	24
221	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	7.1	23
222	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. Journal of the American Heart Association, 2020, 9, e018897.	3.7	23
223	<scp>SCAI</scp> expert consensus statement on out of hospital cardiac arrest. Catheterization and Cardiovascular Interventions, 2020, 96, 844-861.	1.7	23
224	Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovascular Research, 2023, 119, 631-646.	3.8	23
225	Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature Reviews Cardiology, 2014, 11, 693-703.	13.7	22
226	Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq0 0	0 rgBT /C	verlock 10 T 22
227	American Journal of Cardiology, 2014, 113, 930-935. Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non–ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 428-433.	1.6	22
228	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	2.9	22
229	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology, 2018, 34, 319-329.	1.7	22
230	Antithrombotic Treatment after Transcatheter Heart Valves Implant. Seminars in Thrombosis and Hemostasis, 2018, 44, 038-045.	2.7	22
231	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WINâ€₹AVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	1.7	22
232	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	3.0	22
233	Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease. Journal of the American College of Cardiology, 2022, 79, 1398-1406.	2.8	22
234	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	2.9	21

#	Article	IF	Citations
235	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy. JAMA Cardiology, 2020, 5, 939.	6.1	21
236	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	3.9	21
237	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	2.7	21
238	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2022, 79, 1407-1425.	2.8	21
239	Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 384-392.	2.9	20
240	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	2.4	20
241	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2020, 76, 1277-1286.	2.8	20
242	Gender and Disparity in First Authorship in Cardiology Randomized Clinical Trials. JAMA Network Open, 2021, 4, e211043.	5.9	20
243	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567.	3.0	20
244	Usefulness of the SYNTAX Score to Predict Acute Kidney Injury After Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). American Journal of Cardiology, 2014, 113, 1331-1337.	1.6	19
245	Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheterization and Cardiovascular Interventions, 2017, 89, 259-268.	1.7	19
246	Early Ventricular Tachycardia or Fibrillation in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Impact on Mortality and Stent Thrombosis (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial) Tj ETQq0 (o ¹ r&BT/C)verlock 10 1
247	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1997-2005.	3.4	19
248	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	1.6	19
249	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. International Journal of Cardiology, 2019, 283, 67-72.	1.7	19
250	Predictive Value of the Residual SYNTAX Score in Patients With Cardiogenic Shock. Journal of the American College of Cardiology, 2021, 77, 144-155.	2.8	19
251	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and PlateletÂReactivity. JACC: Cardiovascular Interventions, 2021, 14, 417-427.	2.9	19
252	The importance of achieving sex- and gender-based equity in clinical trials: a call to action. European Heart Journal, 2021, 42, 2990-2994.	2.2	19

#	Article	IF	CITATIONS
253	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	1.6	18
254	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 553-561.	2.9	18
255	Shortâ€versus longâ€term Dual Antiplatelet therapy after drugâ€eluting stent implantation in women versus men: A sexâ€specific patientâ€level pooledâ€analysis of six randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 178-189.	1.7	18
256	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2018, 122, 1909-1916.	1.6	18
257	Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2019, 112, 765-772.	1.6	18
258	Rationale and design of the SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial). American Heart Journal, 2022, 243, 92-102.	2.7	18
259	Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). American Journal of Cardiology, 2016, 118, 1097-1104.	1.6	17
260	Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention inÂAcute Coronary Syndromes?. JACC: Cardiovascular Interventions, 2016, 9, 331-337.	2.9	17
261	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and RiskÂfor Adverse EventsÂAmong Patients With and WithoutÂDiabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 645-654.	2.9	17
262	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents) Tj ETQqC	0 0.6 gBT	Owwerlock 10
263	Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. American Heart Journal, 2019, 215, 157-166.	2.7	17
264	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	3.9	17
265	Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical OutcomeÂin Patients With Acute CoronaryÂSyndromes. JACC: Cardiovascular Imaging, 2019, 12, 733-741.	5. 3	17
266	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WINâ€₹AVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 97, 516-526.	1.7	17
267	Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes) Tj ETQq1 1 EuroIntervention, 2013, 9, 817-823.	0.784314	1 1 rgBT /Over <mark>l</mark> o
268	Comparison of Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Discharged on Versus Not on Statin Therapy (from the Harmonizing Outcomes With Revascularization and Stents in) Tj ETQq0	0 0. .rgBT /	/Ov e6 lock 10 1
269	Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). American Journal of Cardiology, 2015, 115, 1389-1395.	1.6	16
270	Anemia and Acute Coronary Syndrome: Time for Intervention Studies. Journal of the American Heart Association, $2016, 5, .$	3.7	16

#	Article	IF	CITATIONS
271	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2016, 117, 192-200.	1.6	16
272	Risk of contrastâ€induced acute kidney injury in STâ€elevation myocardial infarction patients undergoing multiâ€vessel interventionâ€metaâ€analysis of randomized trials and risk prediction modeling study using observational data. Catheterization and Cardiovascular Interventions, 2017, 90, 205-212.	1.7	16
273	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents) Tj ETQq1	l 01 7 &431	4 r g& T /Over
274	Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Review of Cardiovascular Therapy, 2018, 16, 825-835.	1.5	16
275	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. Drugs and Aging, 2019, 36, 531-539.	2.7	16
276	The prevalence, predictors and outcomes of guidelineâ€directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2019, 93, E112-E119.	1.7	16
277	Gender differences in industry payments among cardiologists. American Heart Journal, 2020, 223, 123-131.	2.7	16
278	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. American Heart Journal, 2020, 225, 60-68.	2.7	16
279	Clinical features and prognosis of patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2020, 312, 33-36.	1.7	16
280	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. American Heart Journal, 2017, 194, 73-82.	2.7	15
281	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. International Journal of Cardiology, 2017, 246, 20-25.	1.7	15
282	Guidelines for Patient-Reported Outcomes in Clinical Trial Protocols. JAMA - Journal of the American Medical Association, 2018, 319, 450.	7.4	15
283	Do Patients need Lifelong \hat{l}^2 -Blockers after an Uncomplicated Myocardial Infarction?. American Journal of Cardiovascular Drugs, 2019, 19, 431-438.	2.2	15
284	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	4.1	15
285	Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. Journal of Clinical Medicine, 2020, 9, 3474.	2.4	15
286	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
287	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq1 Cardiology, 2014, 113, 1348-1355.	l 0.78431· 1.6	4 rgBT /Over
288	Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: Lessons from HORIZONS-AMI. American Heart Journal, 2015, 169, 242-248.	2.7	14

#	Article	IF	CITATIONS
289	Platelet Reactivity and Risk of IschemicÂStroke After Coronary Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2018, 11, 1277-1286.	2.9	14
290	Hemoglobin A1c and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 388-397.	2.9	14
291	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. Clinical Pharmacokinetics, 2022, 61, 465-479.	3.5	14
292	Childbearing Among Women Cardiologists. Journal of the American College of Cardiology, 2022, 79, 1076-1087.	2.8	14
293	Coronary Stent Implantation in Patients Committed to Long-term Oral Anticoagulation Therapy. Chest, 2011, 139, 981-987.	0.8	13
294	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute) Tj ETQq0 O	0 ¹ g8T /0	verlöck 10 Tf
295	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2016, 9, e003272.	3.9	13
296	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	1.7	13
297	Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. CardioRenal Medicine, 2019, 9, 160-167.	1.9	13
298	Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry. Catheterization and Cardiovascular Interventions, 2020, 98, 1241-1249.	1.7	13
299	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WINâ€₹AVI) registry. Catheterization and Cardiovascular Interventions, 2020, 96, 198-207.	1.7	13
300	Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial. American Heart Journal, 2021, 232, 185-193.	2.7	13
301	Patients with COVID â€19 who experience a myocardial infarction have complex coronary morphology and high inâ€hospital mortality: Primary results of a nationwide angiographic study. Catheterization and Cardiovascular Interventions, 2021, 98, E370-E378.	1.7	13
302	Evidence base for the management of women with non-ST elevation acute coronary syndrome. Heart, 2022, 108, 1682-1689.	2.9	13
303	Age-Related Effects of Smoking on Coronary Artery Disease Assessed by Gray Scale and Virtual Histology Intravascular Ultrasound. American Journal of Cardiology, 2015, 115, 1056-1062.	1.6	12
304	Efficacy and safety of routine thrombus aspiration in patients with ⟨scp⟩ST⟨ scp⟩â€segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and metaâ€analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2016, 87, 650-660.	1.7	12
305	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	3.9	12
306	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 1166-1172.	1.6	12

#	Article	lF	CITATIONS
307	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	2.9	12
308	Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. Circulation: Cardiovascular Interventions, 2019, 12, e006918.	3.9	12
309	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. International Journal of Cardiology, 2019, 275, 31-35.	1.7	12
310	SCAI multiâ€society position statement on occupational health hazards of the catheterization laboratory: Shifting the paradigm for Healthcare Workers' Protection. Catheterization and Cardiovascular Interventions, 2020, 95, 1327-1333.	1.7	12
311	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient‣evel Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	3.7	12
312	Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2021, 28, 679-686.	1.8	12
313	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. Cardiovascular Diabetology, 2021, 20, 10.	6.8	12
314	Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock. JACC: Cardiovascular Interventions, 2020, 13, 1198-1206.	2.9	12
315	Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210743.	1.7	12
316	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	2.8	12
317	Use of a pneumatic compression system (FEMOSTOPB®) as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. Catheterization and Cardiovascular Diagnosis, 1996, 39, 138-142.	0.3	11
318	Impact of Multiple Complex Plaques on Short- and Long-Term Clinical Outcomes in Patients Presenting With ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With) Tj ETQq0 0 0 rgBT /O of Cardiology, 2014, 113, 1621-1627.	verlock 10 1.6	Tf 50 302 Td
319	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	1.7	11
320	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007124.	3.9	11
321	Impact of insulin treated and nonâ€insulinâ€treated diabetes compared to patients without diabetes on 1â€year outcomes following contemporary PCI. Catheterization and Cardiovascular Interventions, 2020, 96, 298-308.	1.7	11
322	Women and Cardiology: The Value of Diversity. Heart Lung and Circulation, 2021, 30, 3-5.	0.4	11
323	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. International Journal of Cardiology, 2021, 329, 67-73.	1.7	11
324	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 648-659.	3.0	11

#	Article	IF	CITATIONS
325	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	2.8	11
326	Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 81-89.	1.6	11
327	Individualizing treatment choices using quantitative methods. American Heart Journal, 2014, 168, 607-610.	2.7	10
328	Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2016, 68, 2608-2618.	2.8	10
329	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 2017, 120, 904-910.	l 0.78431 1.6	4 rgBT /Ove 10
330	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2018, 46, 346-350.	2.1	10
331	Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. American Heart Journal, 2018, 203, 17-24.	2.7	10
332	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. International Journal of Cardiology, 2019, 297, 22-29.	1.7	10
333	Smallâ€vessel PCI outcomes in men, women, and minorities following platinum chromium everolimusâ€eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Postâ€Approval studies. Catheterization and Cardiovascular Interventions, 2019, 94, 82-90.	1.7	10
334	The Implications of Acute Clinical Care Responsibilities on the Contemporary Practice of Interventional Cardiology. JACC: Cardiovascular Interventions, 2019, 12, 595-599.	2.9	10
335	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	1.5	10
336	Post procedural risk assessment in patients undergoing trans aortic valve implantation according to the age, creatinine, and ejection fractionâ€₹ in stratification of postâ€procedural outcome. Catheterization and Cardiovascular Interventions, 2019, 93, 141-148.	1.7	10
337	Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. JACC: Case Reports, 2020, 2, 1297-1301.	0.6	10
338	Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry. Clinical Research in Cardiology, 2022, 111, 1276-1285.	3.3	10
339	Oneâ€year results of the <scp>ICON</scp> (ionic versus nonâ€ionic contrast to obviate worsening) Tj ETQq1 1 0. Cardiovascular Interventions, 2016, 87, 703-709.	.784314 r _į 1.7	gBT /Overlo 9
340	A null mutation in ANGPTL8 does not associate with either plasma glucose or type 2 diabetes in humans. BMC Endocrine Disorders, 2016, 16, 7.	2.2	9
341	Bleeding After Aortic Valve ReplacementÂMatters. JACC: Cardiovascular Interventions, 2017, 10, 1447-1448.	2.9	9
342	Percutaneous coronary intervention of bifurcation lesions and platelet reactivity. International Journal of Cardiology, 2018, 250, 92-97.	1.7	9

#	Article	IF	CITATIONS
343	Women's Voices in Cardiology. JAMA Cardiology, 2018, 3, 676.	6.1	9
344	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1941-1948.	1.6	9
345	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	1.6	9
346	Treating Inflammation Prior to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009127.	3.9	9
347	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2020, 9, 680.	2.4	9
348	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Cardiovascular Revascularization Medicine, 2022, 34, 17-24.	0.8	9
349	Single Versus Dual Antiplatelet Therapy Following TAVR. JACC: Cardiovascular Interventions, 2021, 14, 234-236.	2.9	9
350	Clinical manifestations and outcomes of coronavirus diseaseâ€19 in heart transplant recipients: a multicentre case series with a systematic review and metaâ€analysis. Transplant International, 2021, 34, 721-731.	1.6	9
351	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2021, 143, 1215-1223.	1.6	9
352	Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, andÂAdverse Outcomes After Successful Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2022, 15, 797-806.	2.9	9
353	Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovascular Revascularization Medicine, 2014, 15, 375-380.	0.8	8
354	Prediction of 1â€year mortality and impact of bivalirudin therapy according to level of baseline risk: A patientâ€level pooled analysis from three randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 391-400.	1.7	8
355	Impact of preâ€existing or newâ€onset atrial fibrillation on 30â€day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1027-1037.	1.7	8
356	Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. American Heart Journal, 2018, 197, 142-149.	2.7	8
357	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and metaâ€analysis. Cardiovascular Therapeutics, 2018, 36, e12457.	2.5	8
358	Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study). American Journal of Cardiology, 2019, 124, 1380-1388.	1.6	8
359	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	1.7	8
360	Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France. Archives of Cardiovascular Diseases, 2019, 112, 670-679.	1.6	8

#	Article	IF	Citations
361	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WINâ€₹AVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	1.7	8
362	Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. Thrombosis and Haemostasis, 2021, 121, 854-866.	3.4	8
363	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2022, 53, 20-29.	2.1	8
364	Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. IJC Heart and Vasculature, 2020, 30, 100634.	1.1	8
365	Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal, 2014, 167, 43-50.	2.7	7
366	Antiplatelet therapy after drug-eluting stent implantation. Journal of Cardiology, 2015, 65, 98-104.	1.9	7
367	CABG surgery versus PCI in CAD—surgery strikes again!. Nature Reviews Cardiology, 2015, 12, 75-77.	13.7	7
368	The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. Progress in Cardiovascular Diseases, 2015, 58, 247-259.	3.1	7
369	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. Circulation, 2019, 140, 1960-1963.	1.6	7
370	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	1.6	7
371	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Canadian Journal of Cardiology, 2019, 35, 199-207.	1.7	7
372	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004945.	2.2	7
373	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. American Heart Journal, 2019, 207, 10-18.	2.7	7
374	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 435-450.	2.8	7
375	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. Archives of Cardiovascular Diseases, 2020, 113, 797-810.	1.6	7
376	Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences. Circulation, 2021, 143, 755-757.	1.6	7
377	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. Clinical Research in Cardiology, 2021, 110, 649-657.	3.3	7
378	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	1.7	7

#	Article	IF	CITATIONS
379	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. Journal of Clinical Medicine, 2021, 10, 4005.	2.4	7
380	Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures. EuroIntervention, 2017, 13, 1226-1233.	3.2	7
381	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	1.6	6
382	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. JAMA Cardiology, 2017, 2, 673.	6.1	6
383	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
384	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. Journal of Cardiology, 2018, 71, 494-504.	1.9	6
385	Paravalvular Leak. Journal of the American College of Cardiology, 2018, 72, 2149-2151.	2.8	6
386	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. American Heart Journal, 2018, 205, 77-86.	2.7	6
387	Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials. International Journal of Cardiology, 2018, 266, 75-80.	1.7	6
388	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	3.9	6
389	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). American Journal of Cardiology, 2019, 123, 355-360.	1.6	6
390	Residual angina in female patients after coronary revascularization. International Journal of Cardiology, 2019, 286, 208-213.	1.7	6
391	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the) Tj ETQq $1\ 1\ 0.7$	⁷ 8413d.4 rg	BT&Overloc
392	Impact of stent diameter on outcomes following percutaneous coronary intervention with secondâ€generation drugâ€eluting stents: Results from a large singleâ€center registry. Catheterization and Cardiovascular Interventions, 2020, 96, 558-564.	1.7	6
393	Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. Journal of Women's Health, 2020, 29, 1150-1159.	3.3	6
394	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. JACC: Cardiovascular Interventions, 2020, 13, 2882-2892.	2.9	6
395	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. American Heart Journal, 2020, 225, 27-37.	2.7	6
396	Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	6

#	Article	IF	Citations
397	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. Catheterization and Cardiovascular Interventions, 2021, 97, 63-71.	1.7	6
398	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. Circulation: Cardiovascular Interventions, 2021, 14, e010392.	3.9	6
399	Gender Differences in Medicare Payments Among Cardiologists. JAMA Cardiology, 2021, 6, 1432.	6.1	6
400	Coronary artery disease in the young in the US population-based cohort. American Journal of Cardiovascular Disease, 2020, 10, 189-194.	0.5	6
401	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6
402	Outcomes Following Patent Foramen Ovale Percutaneous Closure According to the Delay From Last Ischemic Event. Canadian Journal of Cardiology, 2022, 38, 1228-1234.	1.7	6
403	Current State and Future Perspectives of Artificial Intelligence for Automated Coronary Angiography Imaging Analysis in Patients with Ischemic Heart Disease. Current Cardiology Reports, 2022, 24, 365-376.	2.9	6
404	Cardiogenic Shock in Women. Interventional Cardiology Clinics, 2012, 1, 231-243.	0.4	5
405	Cardiac manifestations in sickle cell disease varies with patient genotype. British Journal of Haematology, 2018, 181, 664-671.	2.5	5
406	Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?. Interventional Cardiology Review, 2018, 13, 1.	1.6	5
407	Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. Circulation: Cardiovascular Interventions, 2019, 12, e008296.	3.9	5
408	Adjunct Pharmacotherapy After Transcatheter Aortic Valve Replacement. Interventional Cardiology Clinics, 2019, 8, 357-371.	0.4	5
409	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary interventionâ€"Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2020, 95, 885-892.	1.7	5
410	Coronary artery disease in systemic lupus: A case-controlled angiographic study. Autoimmunity Reviews, 2020, 19, 102427.	5.8	5
411	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2020, 96, E377-E386.	1.7	5
412	Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy. Expert Review of Medical Devices, 2020, 17, 257-265.	2.8	5
413	Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2020, 113, 341-349.	1.6	5
414	Oneâ€year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 97, 1341-1351.	1.7	5

#	Article	IF	CITATIONS
415	Angiographic predictors of outcome in myocardial infarction patients presenting with cardiogenic shock: a CULPRIT-SHOCK angiographic substudy. EuroIntervention, 2021, 16, e1237-e1244.	3.2	5
416	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 150, 15-23.	1.6	5
417	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. Future Cardiology, 2020, 16, 613-623.	1.2	5
418	Endothelial Progenitor Cells in Coronary Atherosclerosis and Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2022, 42, 94-99.	0.8	5
419	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	3.0	5
420	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	3.2	5
421	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	3.2	5
422	Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCl—rationale and study design of the prospective observational multicenter AVIATOR 2 registry. American Heart Journal, 2015, 170, 1234-1242.	2.7	4
423	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment– Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	4
424	"Capturing―the Benefits of Dual-TherapyÂStent Technology. JACC: Cardiovascular Interventions, 2016, 9, 1135-1137.	2.9	4
425	Effect of valve design and anticoagulation strategy on 30â€day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	1.7	4
426	Nonâ€femoral TAVR: Time to stratify alternative vascular approaches. Catheterization and Cardiovascular Interventions, 2018, 92, 1194-1195.	1.7	4
427	Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. American Journal of Cardiology, 2019, 124, 1363-1371.	1.6	4
428	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	1.7	4
429	Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovascular Research, 2020, 116, e70-e72.	3.8	4
430	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vsAMultivessel PCI in Cardiogenic Shock Trial. Chest, 2021, 159, 1415-1425.	0.8	4
431	Performance of Prediction Models for Contrast-Induced Acute Kidney Injury after Transcutaneous Aortic Valve Replacement. CardioRenal Medicine, 2021, 11, 166-173.	1.9	4
432	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. American Journal of Cardiovascular Drugs, 2021, 21, 681-691.	2.2	4

#	Article	IF	CITATIONS
433	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	2.1	4
434	Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. EuroIntervention, 2014, 10, 97-104.	3.2	4
435	Outcomes of Transcatheter Aortic Valve Implantation in Patients With Chronic and End-Stage Kidney Disease. American Journal of Cardiology, 2022, 164, 100-102.	1.6	4
436	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	1.6	4
437	The Heart Team for Coronary Revascularization Decisions. JACC: Case Reports, 2022, 4, 115-120.	0.6	4
438	Device and Procedure Relatedness. JACC: Cardiovascular Interventions, 2022, 15, 783-788.	2.9	4
439	Patient partnership in cardiovascular clinical trials. European Heart Journal, 2022, 43, 1432-1437.	2.2	4
440	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	1.6	4
441	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
442	Postprocedural Anticoagulation for Specific Therapeutic Indications After Revascularization for ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization) Tj ETQq0	0 0.6 gBT /	Oværlock 10
443	Impact of Pre-Procedural Cardiopulmonary Instability in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Harmonizing Outcomes With) Tj ETQq1 1 0.7 2014, 114, 962-967.	784314 rg 1.6	;BT ₃ /Overlock
444	Poor mobility independently predicts mortality in <scp>TAVI</scp> : Are we closer to a universal definition for frailty?. Catheterization and Cardiovascular Interventions, 2015, 86, 1278-1279.	1.7	3
445	Same or next day discharge: A new chapter in transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2016, 87, 143-144.	1.7	3
446	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	2.1	3
447	Ticagrelor Monotherapy After CoronaryÂStenting. Journal of the American College of Cardiology, 2019, 74, 2235-2237.	2.8	3
448	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. American Heart Journal, 2019, 211, 68-76.	2.7	3
449	The Opportunity of Women as One. JACC: Case Reports, 2020, 2, 2044-2046.	0.6	3
450	TAVR. JACC: Cardiovascular Interventions, 2020, 13, 2667-2669.	2.9	3

#	Article	IF	Citations
451	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovascular Revascularization Medicine, 2020, 21, 1542-1547.	0.8	3
452	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	1.7	3
453	Prevalence and prognostic impact of hsCRP elevation are ageâ€dependent in women but not in men undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, E936-E944.	1.7	3
454	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. Future Cardiology, 2021, 17, 521-534.	1.2	3
455	Culprit lesion location and outcomes in patients with multivessel disease and infarct-related cardiogenic shock: a core laboratory analysis of the CULPRIT-SHOCK trial. EuroIntervention, 2021, 17, e418-e424.	3.2	3
456	Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. European Journal of Clinical Investigation, 2022, 52, e13664.	3.4	3
457	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1â€month dual antiplatelet therapy following ⟨scp⟩PCI⟨/scp⟩: Analysis from the ⟨scp⟩Onyx ONE⟨/scp⟩ clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	1.7	3
458	GLOBAL LEADERS: looking now at the bigger picture. EuroIntervention, 2019, 15, e1030-e1032.	3.2	3
459	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC: Cardiovascular Interventions, 2021, 14, 2447-2457.	2.9	3
460	The year in cardiovascular medicine 2021: interventional cardiology. European Heart Journal, 2022, 43, 377-386.	2,2	3
461	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions â€" proceedings from the CEC Summit 2018. American Heart Journal, 2022, 246, 93-104.	2.7	3
462	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. Current Cardiology Reports, 2022, 24, 277-293.	2.9	3
463	Revascularization or optimal medical therapy for stable ischemic heart disease: A Bayesian meta-analysis of contemporary trials. Cardiovascular Revascularization Medicine, 2021, , .	0.8	3
464	Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement. Journal of Clinical Medicine, 2022, 11, 2190.	2.4	3
465	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology, 2022, 7, 682.	6.1	3
466	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 266-275.	2.9	2
467	Drug-eluting stents and drug-eluting balloons are the best strategies to treat coronary in-stent restenosis. Evidence-Based Medicine, 2016, 21, 90-90.	0.6	2
468	Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non–ST-elevation acute coronary syndrome. American Heart Journal, 2017, 187, 112-121.	2.7	2

#	Article	IF	CITATIONS
469	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	3.4	2
470	Use of prasugrel and clinical outcomes in Africanâ€American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2019, 94, 53-60.	1.7	2
471	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	1.7	2
472	Drugâ€eluting stents in diabetic patients: Are we still treading water?. Catheterization and Cardiovascular Interventions, 2020, 96, 253-254.	1.7	2
473	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2020, 9, 265-278.	0.4	2
474	The Conundrum and Opportunity of Gender Equity for Evidence Generators. JAMA Cardiology, 2020, 5, 623.	6.1	2
475	Pregnancy during cardiology training: a call to action. Heart, 2021, 107, 1018-1019.	2.9	2
476	Aspirin-Free Strategies in ACS. JACC: Cardiovascular Interventions, 2021, 14, 441-443.	2.9	2
477	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	2.1	2
478	Impact of sex on longâ€term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2021, 98, E494-E500.	1.7	2
479	Impact of anemia on shortâ€term outcomes after TAVR : A subgroup analysis from the BRAVO â€3 randomized trial. Catheterization and Cardiovascular Interventions, 2021, 98, E870-E880.	1.7	2
480	Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries. American Heart Journal, 2021, 236, 37-48.	2.7	2
481	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010458.	3.9	2
482	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheterization and Cardiovascular Interventions, 2021, 98, E785-E795.	1.7	2
483	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. Annals of Translational Medicine, 2017, 5, 261-261.	1.7	2
484	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2022, 38, 792-800.	1.7	2
485	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	2
486	Independence of clinical events committees: A consensus statement from clinical research organizations. American Heart Journal, 2022, 248, 120-129.	2.7	2

#	Article	IF	CITATIONS
487	Timing of invasive management of NSTE-ACS: is the time up for early management?. European Heart Journal, 2022, 43, 3161-3163.	2.2	2
488	Elderly patients with acute myocardial infarction: Targeted or complete revascularization?. Catheterization and Cardiovascular Interventions, 2022, 99, 979-980.	1.7	2
489	Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon. European Heart Journal, 2022, 43, 3145-3147.	2.2	2
490	Predicting Risk of Ischemic or Bleeding Events After Percutaneous Coronary Intervention. JAMA Cardiology, 2016, 1, 731.	6.1	1
491	The Triple Challenge of Triple Therapy. JACC: Cardiovascular Interventions, 2016, 9, 1703-1705.	2.9	1
492	Arterial hypertension: A neglected risk for bleeding. Catheterization and Cardiovascular Interventions, 2016, 88, 191-192.	1.7	1
493	Equal sex-based outcomes in unprotected left main PCI: No advantage for men. International Journal of Cardiology, 2018, 253, 61-63.	1.7	1
494	Interventional Standby for CABG Surgery. Journal of the American College of Cardiology, 2019, 73, 424-426.	2.8	1
495	Left Atrial Appendage Closure. JACC: Cardiovascular Interventions, 2019, 12, 1077-1079.	2.9	1
496	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions, 2019, 12, e008160.	3.9	1
497	Examining the role of diabetes mellitus in STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2019, 94, 926-927.	1.7	1
498	Feasibility of measuring patient-reported health status at time of percutaneous coronary intervention: Results from a single-center quality-improvement initiative. European Journal of Preventive Cardiology, 2020, 27, 2183-2186.	1.8	1
499	Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2020, 125, 685-693.	1.6	1
500	Side branch fractional flow reserve after provisional stenting of calcified bifurcation lesions: The <scp>ORBIDâ€FFR</scp> study. Catheterization and Cardiovascular Interventions, 2021, 98, 658-668.	1.7	1
501	Towards a standardized classification of cardiogenic shock: Will the new <scp>SCAI</scp> staging system translate into better clinical practice and research?. Catheterization and Cardiovascular Interventions, 2020, 96, 1348-1349.	1.7	1
502	Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess?. Annals of Translational Medicine, 2020, 8, 556-556.	1.7	1
503	Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large singleâ€center registry. Catheterization and Cardiovascular Interventions, 2020, 96, E278-E286.	1.7	1
504	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVOâ€3 trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	1.7	1

#	Article	IF	CITATIONS
505	Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention. European Heart Journal, 2021, 42, 2710-2711.	2.2	1
506	Single antiplatelet therapy after transcatheter aortic valve implantation: clarity on existing data. European Heart Journal, 2021, 42, 3203-3204.	2.2	1
507	Stick to the guidelines or clinical judgment: A toss up?. International Journal of Cardiology, 2021, 338, 83-84.	1.7	1
508	Sex disparities continue to characterise the management of nonâ€STâ€elevation acute coronary syndrome. Medical Journal of Australia, 2021, , .	1.7	1
509	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. Cardiovascular Revascularization Medicine, 2022, , .	0.8	1
510	Women leaders: transforming the culture in cardiology. Open Heart, 2022, 9, e001967.	2.3	1
511	Impact of transit-time flow measurement on early postoperative outcomes in total arterial coronary revascularization with internal thoracic arteries: a propensity score analysis on 910 patients. Interactive Cardiovascular and Thoracic Surgery, 2022, 35, .	1.1	1
512	Readmission in Patients With ST-Elevation Myocardial Infarction in 4 Age Groups (<45, >45 to) Tj ETQq0 0	0 rgBT /Ον	erlock 10 Tf 5
513	Future Perspectives on Percutaneous Coronary Interventions in Women. Interventional Cardiology Clinics, 2012, 1, 251-258.	0.4	0
514	The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2012, 1, 441-451.	0.4	0
515	Coronary Artery Disease in Women: Shyly Bold?. Interventional Cardiology Clinics, 2012, 1, ix-x.	0.4	0
516	CABG Beats Vintage PCI. JACC: Cardiovascular Interventions, 2016, 9, 2508-2510.	2.9	0
517	<scp>STEMI</scp> with multivessel disease: An ongoing battle for the optimal treatment strategy. Catheterization and Cardiovascular Interventions, 2016, 88, 707-708.	1.7	O
518	Orbital atherectomy for severely calcified lesions: More dissections in women but similar 30â€day outcomes to men. Catheterization and Cardiovascular Interventions, 2016, 87, 678-679.	1.7	0
519	Target lesion failure with <scp>BRS</scp> ? good old <scp>DES</scp> to the rescue. Catheterization and Cardiovascular Interventions, 2016, 87, 837-838.	1.7	O
520	REGULATE-PCI trial – Author's reply. Lancet, The, 2016, 387, 1510-1511.	13.7	0
521	Minding the Microcirculation. Circulation: Cardiovascular Interventions, 2019, 12, e008312.	3.9	0
522	Limitations of Current Risk Scoring in Real World Populations: The Importance of External Validation. Revista Espanola De Cardiologia (English Ed), 2019, 72, 192-194.	0.6	0

#	Article	IF	CITATIONS
523	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	1.6	0
524	Oneâ€year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2020, , .	1.7	0
525	Transcatheter aortic valve replacement in patients with <scp>endâ€stage</scp> renal disease: Is "better than nothing―good enough?. Catheterization and Cardiovascular Interventions, 2020, 96, 1110-1112.	1.7	0
526	Panta rhei, also drug eluting stent technology. Catheterization and Cardiovascular Interventions, 2020, 95, 1074-1075.	1.7	0
527	Ticagrelor in Patients With Cancer. JACC: CardioOncology, 2020, 2, 251-253.	4.0	0
528	Gender-related differences after acute myocardial infarction: A major global health challenge. International Journal of Cardiology, 2020, 311, 18-19.	1.7	0
529	Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. American Heart Journal, 2020, 223, 84-86.	2.7	0
530	Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting. Journal of Cardiology, 2021, 77, 93-99.	1.9	0
531	Bivalirudin versus heparin in PCI: Is the pendulum swinging again in favor of heparin?. Catheterization and Cardiovascular Interventions, 2021, 97, 774-775.	1.7	0
532	The 70/30 Rule Between Men and Womenâ€"Disparity or Opportunity?â€"Reply. JAMA Cardiology, 2021, 6, 482.	6.1	0
533	White blood cell count and clinical outcomes after left main coronary artery revascularization. Coronary Artery Disease, 2021, Publish Ahead of Print, 45-51.	0.7	0
534	Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. American Journal of Cardiology, 2021, 148, 165-171.	1.6	0
535	Access routes in transcatheter aortic valve replacement: All roads lead to Rome but only one is paved. Catheterization and Cardiovascular Interventions, 2021, 97, 1470-1471.	1.7	0
536	Interventions in Ischemic Heart Disease., 2021,, 93-108.		0
537	Patient-tailored Drug-eluting Stent Choice – A Solution for Patients with Diabetes. Interventional Cardiology Review, 2015, 10, 158.	1.6	0
538	Comments from the Expert. Indian Journal of Cardiovascular Disease in Women WINCARS, 2020, 5, 174-174.	0.1	0
539	Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Interventionâ€"Reply. JAMA Cardiology, 2022, , .	6.1	0
540	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology, 2022, , .	1.6	0

#	Article	IF	CITATIONS
541	Perspectives of Female Cardiology Trainees on Interventional Cardiology Training and Careers: A Canadian Nationwide Survey. Canadian Journal of Cardiology, 2022, , .	1.7	O
542	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart, 2022, 9, e001892.	2.3	0
543	Inclusion of women in cardiovascular clinical trials: A path forward. Contemporary Clinical Trials, 2022, 115, 106719.	1.8	O
544	Rethinking the Role of Impaired Renal Function in Multivessel PCI or CABG. Journal of the American College of Cardiology, 2022, 79, 1285-1287.	2.8	0
545	291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy. European Heart Journal Supplements, 2021, 23, .	0.1	O
546	The Final Word: Current Strategies for the Lifetime Management of Patients with Aortic Valve Stenosis. US Cardiology Review, 0, 16 , .	0.5	0